LA JOLLA, Calif., May 23, 2016 /PRNewswire/ -- Regulus
Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company
leading the discovery and development of innovative medicines
targeting microRNAs, announced today that Allison Wey has been appointed Vice President,
Investor Relations and Corporate Communications. Ms. Wey
brings over 25 years of experience in investor relations, corporate
communications, media relations and investment banking.
"Allison's broad background in investor relations will prove
valuable as the company's pipeline matures," said Jay Hagan, Chief Operating Officer of
Regulus. "We are pleased to welcome Allison, and we look
forward to her contributions in communicating the strong potential
of Regulus' pipeline."
"Regulus is leading the way in developing important new
therapies focused on microRNA dysregulation to treat a wide range
of diseases," said Allison Wey.
"I'm excited to join the Regulus team in advancing its broad
portfolio."
Prior to joining Regulus, Ms. Wey was Vice President, Investor
Relations for Durata Therapeutics up until its acquisition by
Actavis. Before Durata, Ms. Wey served as Vice President,
Investor Relations and Corporate Affairs at Par Pharmaceuticals
from 2007 until its acquisition by TPG. Ms. Wey also has
extensive experience in media relations and corporate
communications including working as VP, Investor Relations at
Boron, LePore & Associates, Senior VP at Edelman Financial
Worldwide, Managing Director, Financial Communications at Hill
& Knowlton, and Associate Director, Equity Capital Markets at
Bear, Stearns & Co. Inc.
About Regulus
Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical
company leading the discovery and development of innovative
medicines targeting microRNAs. Regulus has leveraged its
oligonucleotide drug discovery and development expertise to develop
a well-balanced microRNA therapeutics pipeline complemented by a
maturing microMarkersSM biomarkers platform and a rich
intellectual property estate to retain its leadership in the
microRNA field. Regulus is developing RG-101, a
GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment
of chronic hepatitis C virus infection, and RG-012, an anti-miR
targeting microRNA-21 for the treatment of Alport syndrome, a
life-threatening kidney disease driven by genetic mutations with no
approved therapy. In addition, RG-125, a GalNAc-conjugated
anti-miR targeting microRNA-103/107 for the treatment of NASH in
patients with type 2 diabetes/pre-diabetes, has entered Phase I
clinical development through its strategic alliance with
AstraZeneca. Regulus is also advancing several programs
toward clinical development in renal, hepatic and central nervous
systems diseases, both independently and with our strategic
alliance partners, Sanofi and AstraZeneca. Regulus'
commitment to innovation has resulted in multiple peer-reviewed
publications in notable scientific journals and has resulted in the
formation of strategic alliances with AstraZeneca and Sanofi.
Regulus maintains its corporate headquarters in La Jolla, CA. For more information,
please visit http://www.regulusrx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements associated with the expected ability
of Regulus to undertake certain activities and accomplish certain,
the projected timeline of clinical development activities, and
expectations regarding future therapeutic and commercial potential
of Regulus' business plans, technologies and intellectual property
related to microRNA therapeutics and biomarkers being discovered
and developed by Regulus. Because such statements are subject
to risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects,"
"intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are based upon Regulus' current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of
events could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, risks associated
with the process of discovering, developing and commercializing
drugs that are safe and effective for use as human therapeutics,
and in the endeavor of building a business around such drugs.
These and other risks concerning Regulus' financial position and
programs are described in additional detail in Regulus filings with
the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Regulus undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
Logo - http://photos.prnewswire.com/prnh/20160519/370141LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/regulus-appoints-allison-wey-as-vice-president-investor-relations--corporate-communications-300272578.html
SOURCE Regulus Therapeutics Inc.